Rhythm Biosciences Limited, a transformative diagnostics company, engages in developing and commercializing of medical diagnostics technology in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.22|
|52 Week High||AU$0.18|
|52 Week Low||AU$1.68|
|1 Month Change||6.55%|
|3 Month Change||29.10%|
|1 Year Change||408.33%|
|3 Year Change||741.39%|
|5 Year Change||n/a|
|Change since IPO||275.39%|
Recent News & Updates
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Rhythm Biosciences...
|RHY||AU Healthcare||AU Market|
Return vs Industry: RHY exceeded the Australian Healthcare industry which returned 11.5% over the past year.
Return vs Market: RHY exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: RHY is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: RHY's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
Rhythm Biosciences Limited, a transformative diagnostics company, engages in developing and commercializing of medical diagnostics technology in Australia and internationally. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Fundamentals Summary
|RHY fundamental statistics|
Is RHY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RHY income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.032|
|Net Profit Margin||-596.49%|
How did RHY perform over the long term?See historical performance and comparison
Is Rhythm Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RHY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RHY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RHY is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: RHY is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RHY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RHY is overvalued based on its PB Ratio (149.3x) compared to the AU Healthcare industry average (2.1x).
How is Rhythm Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RHY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: RHY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RHY's is expected to become profitable in the next 3 years.
Revenue vs Market: RHY is forecast to have no revenue next year.
High Growth Revenue: RHY is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RHY's Return on Equity is forecast to be high in 3 years time
How has Rhythm Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RHY is currently unprofitable.
Growing Profit Margin: RHY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RHY is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.
Accelerating Growth: Unable to compare RHY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RHY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: RHY has a negative Return on Equity (-387.4%), as it is currently unprofitable.
How is Rhythm Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: RHY's short term assets (A$2.5M) exceed its short term liabilities (A$1.3M).
Long Term Liabilities: RHY's short term assets (A$2.5M) exceed its long term liabilities (A$19.7K).
Debt to Equity History and Analysis
Debt Level: RHY is debt free.
Reducing Debt: RHY had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RHY has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RHY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.9% each year
What is Rhythm Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RHY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RHY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RHY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RHY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RHY's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Glenn Gilbert has been Chief Executive Officer of Rhythm Biosciences Limited since November 27, 2018 and had been its Chief Operating Officer since May 21, 2018 until November 27, 2018. Mr. Gilbert ser...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD409.21K) is about average for companies of similar size in the Australian market ($USD555.78K).
Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.
Experienced Management: RHY's management team is considered experienced (3 years average tenure).
Experienced Board: RHY's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RHY insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
Rhythm Biosciences Limited's employee growth, exchange listings and data sources
- Name: Rhythm Biosciences Limited
- Ticker: RHY
- Exchange: ASX
- Founded: 2017
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$254.736m
- Shares outstanding: 208.80m
- Website: https://www.rhythmbio.com
- Rhythm Biosciences Limited
- Bio21 Institute
- 30 Flemington Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.